The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma. (2017)

Peer-Reviewed Study · Cynthia M Simbulan-Rosenthal; Sivanesan Dakshanamurthy; Anirudh Gaur et al. · February 21, 2017

Cynthia M Simbulan-Rosenthal et al., 2017-02-21: Simbulan-Rosenthal et al. show mebendazole binds BRAF and synergises with trametinib against NRAS-mutant melanoma in culture and in xenografts.

We find that MBZ synergizes with the MEK inhibitor trametinib to inhibit growth of BRAFWT-NRASQ61K melanoma cells in culture and in xenografts, and markedly decreased MEK and ERK phosphorylation.

Cynthia M Simbulan-Rosenthal et al., 2017-02-21: Simbulan-Rosenthal et al. show mebendazole binds BRAF and synergises with trametinib against NRAS-mutant melanoma in culture and in xenografts. Study type: melanoma cell lines plus mouse xenografts. N: not stated in the abstract. Country: USA (Georgetown University Medical Center). Dose: not stated in the abstract text captured. Funder: US NIH P30 CA051008 and R01 CA170653. Declared conflicts: 'The authors declare no conflicts of interest.' Comparator: trametinib alone and vehicle. Study type: animal.